Line 5: |
Line 5: |
| {| class="wikitable" | | {| class="wikitable" |
| |- | | |- |
− | ! Chromosome | + | !Chromosome |
− | ! AML Subtype | + | !AML Subtype |
− | ! Abnormality Type (Amplification, Loss, CN-LOH) | + | !Abnormality Type (Amplification, Loss, CN-LOH) |
− | ! Region | + | !Region |
− | ! Relevant Genes (if known) | + | !Relevant Genes (if known) |
− | ! Clinical Significance | + | !Clinical Significance |
− | ! Level of Evidence | + | !Level of Evidence |
| + | !References |
| |- | | |- |
− | | 1 | + | |1 |
− | | AML including NK-AML | + | |AML including NK-AML |
− | | CN-LOH | + | |CN-LOH |
− | | 1p | + | |1p |
− | | | + | | |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 2 | + | |2 |
− | | AML | + | |AML |
− | | CN-LOH | + | |CN-LOH |
− | | 2p | + | |2p |
− | | ''DNMT3A'' | + | |''[[DNMT3A]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 3 | + | |3 |
− | | NK-AML, sAML | + | |NK-AML, sAML |
− | | Loss | + | |Loss |
− | | 3p14.1 | + | |3p14.1 |
− | | ''FOXP1'' | + | |''[[FOXP1]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 4 | + | |4 |
− | | sAML, pAML | + | |sAML, pAML |
− | | CN-LOH | + | |CN-LOH |
− | | 4q24 | + | |4q24 |
− | | ''TET2'' | + | |''[[TET2]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 4 | + | |4 |
− | | AML, NK-AML, sAML | + | |AML, NK-AML, sAML |
− | | Loss | + | |Loss |
− | | 4q24 | + | |4q24 |
− | | ''TET2'' | + | |''[[TET2]]'' |
− | | D, P | + | |D, P |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 5 | + | |5 |
− | | pAML, sAML | + | |pAML, sAML |
− | | Loss | + | |Loss |
− | | 5q | + | |5q |
− | | | + | | |
− | | D | + | |D |
− | | 1 | + | |1 |
| + | | |
| |- | | |- |
− | | 6 | + | |6 |
− | | AML including NK-AML | + | |AML including NK-AML |
− | | CN-LOH | + | |CN-LOH |
− | | 6p | + | |6p |
− | | | + | | |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 7 | + | |7 |
− | | AML including NK-AML | + | |AML including NK-AML |
− | | CN-LOH | + | |CN-LOH |
− | | 7q | + | |7q |
− | | ''EZH2'' | + | |''[[EZH2]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 7 | + | |7 |
− | | NK-AML, pAML, sAML | + | |NK-AML, pAML, sAML |
− | | Loss | + | |Loss |
− | | 7q | + | |7q |
− | | ''EZH2, CUX1'' | + | |''[[EZH2]], [[CUX1]]'' |
− | | D | + | |D |
− | | 1 | + | |1 |
| + | | |
| |- | | |- |
− | | 8 | + | |8 |
− | | AML with complex karyotype | + | |AML with complex karyotype |
− | | Amplification | + | |Amplification |
− | | 8q24 | + | |8q24 |
− | | ''MYC'' | + | |''[[MYC]]'' |
− | | D, P | + | |D, P |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 9 | + | |9 |
− | | NK-AML, sAML | + | |NK-AML, sAML |
− | | CN-LOH | + | |CN-LOH |
− | | 9p | + | |9p |
− | | ''JAK2'' | + | |''[[JAK2]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 11* | + | |11* |
− | | AML with complex karyotype | + | |AML with complex karyotype |
− | | Amplification | + | |Amplification |
− | | 11q23 | + | |11q23 |
− | | ''MLL (KMT2A)'' | + | |''[[KMT2A|MLL (KMT2A)]]'' |
− | | D, P | + | |D, P |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 11* | + | |11* |
− | | AML | + | |AML |
− | | CN-LOH | + | |CN-LOH |
− | | 11p | + | |11p |
− | | ''WT1'' | + | |''[[WT1]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 11 | + | |11 |
− | | pAML, sAML, NK-AML | + | |pAML, sAML, NK-AML |
− | | CN-LOH | + | |CN-LOH |
− | | 11q | + | |11q |
− | | ''CBL'' | + | |''[[CBL]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 12 | + | |12 |
− | | AML, NK-AML, AML with complex karyotype, sAML | + | |AML, NK-AML, AML with complex karyotype, sAML |
− | | Loss | + | |Loss |
− | | 12p13.2 | + | |12p13.2 |
− | | ''ETV6'' | + | |''[[ETV6]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 13* | + | |13* |
− | | pAML, NK-AML, ''NPM1'' mutated AML, FLT3-ITD positive AML, sAML | + | |pAML, NK-AML, ''NPM1'' mutated AML, FLT3-ITD positive AML, sAML |
− | | CN-LOH | + | |CN-LOH |
− | | 13q | + | |13q |
− | | ''FLT3'' | + | |''[[FLT3]]'' |
− | | D, P | + | |D, P |
− | | 2 | + | |2 |
| + | | |
| |- | | |- |
− | | 16 | + | |16 |
− | | NK-AML, AML with complex karyotype, pAML, sAML | + | |NK-AML, AML with complex karyotype, pAML, sAML |
− | | Loss | + | |Loss |
− | | 16q | + | |16q |
− | | ''CBFB'' | + | |''[[CBFB]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 17 | + | |17 |
− | | AML, NK-AML, pAML, sAML | + | |AML, NK-AML, pAML, sAML |
− | | CN-LOH | + | |CN-LOH |
− | | 17p | + | |17p |
− | | ''TP53'' | + | |''[[TP53]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 17 | + | |17 |
− | | sAML, NK-AML, AML with complex karyotype, ''de novo'' AML | + | |sAML, NK-AML, AML with complex karyotype, ''de novo'' AML |
− | | Loss | + | |Loss |
− | | 17p | + | |17p |
− | | ''TP53'' | + | |''[[TP53]]'' |
− | | D, P | + | |D, P |
− | | 1 | + | |1 |
| + | | |
| |- | | |- |
− | | 17 | + | |17 |
− | | NK-AML, pAML | + | |NK-AML, pAML |
− | | Loss | + | |Loss |
− | | 17q11.2 | + | |17q11.2 |
− | | ''NF1, SUZ12'' | + | |''[[NF1]], [[SUZ12]]'' |
− | | D, P | + | |D, P |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 19* | + | |19* |
− | | AML, NK-AML, sAML | + | |AML, NK-AML, sAML |
− | | CN-LOH | + | |CN-LOH |
− | | 19q | + | |19q |
− | | ''CEBPA'' | + | |''[[CEBPA]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 20 | + | |20 |
− | | sAML | + | |sAML |
− | | Loss | + | |Loss |
− | | 20q | + | |20q |
− | | | + | | |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 21* | + | |21* |
− | | pAML, AML with complex karyotype | + | |pAML, AML with complex karyotype |
− | | Amplification | + | |Amplification |
− | | 21q22 | + | |21q22 |
− | | ''ERG, ETS2'' | + | |''[[ERG]], [[ETS2]]'' |
− | | D, P, T | + | |D, P, T |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 21* | + | |21* |
− | | AML, NK-AML, sAML | + | |AML, NK-AML, sAML |
− | | CN-LOH | + | |CN-LOH |
− | | 21q | + | |21q |
− | | ''RUNX1'' | + | |''[[RUNX1]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
− | | 21* | + | |21* |
− | | sAML | + | |sAML |
− | | Loss | + | |Loss |
− | | 21q22.12 | + | |21q22.12 |
− | | ''RUNX1'' | + | |''[[RUNX1]]'' |
− | | D | + | |D |
− | | 3 | + | |3 |
| + | | |
| |- | | |- |
| |} | | |} |
Line 223: |
Line 249: |
| | | |
| 1. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018). Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet [Epub ahead of print], PMID 30344013. | | 1. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018). Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet [Epub ahead of print], PMID 30344013. |
| + | |
| + | 2. Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer 2015;121:2900–8, PMID 26033747 |